Autopsy report · NCT02122172

Afatinib in Advanced Refractory Urothelial Cancer

“Unable to meet accrual goal after several years”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 5 months before it started.
• Ran for about 6 years 7 months before it stopped.
• 32 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Chicago

Sponsor type

University, hospital or other

Conditions

Distal Urethral Cancer; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Urethral Cancer; Stage III Bladder Cancer; Stage III Urethral Cancer

Interventions

afatinib dimaleate; laboratory biomarker analysis

Participants

32

Sites

6

Countries

United States

Trials that died the same way

• Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
  “Unable to meet accrual goals” (87% match in meaning)
• Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
  “Failure to meet accrual goals.” (71% match in meaning)
• Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery
  “No accrual last 2 years” (68% match in meaning)
• Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
  “Accrual Goal met” (68% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.